Clinical Trial Update: Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/Phase 2 clinical trial evaluating the immune response to a MUC1 peptide vaccine in patients with non-small cell lung cancer; the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MUC1 peptide vaccine (MUC1 peptide vaccine)

Snippet

Sponsor: Olivera Finn | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: RECRUITING